dr. rugo on the optimal setting for biosimilar evaluation
Published 5 years ago • 47 plays • Length 1:35Download video MP4
Download video MP3
Similar videos
-
1:37
dr. rugo discusses the regulatory process behind biosimilars
-
1:43
dr. rugo discusses the equivalency of trastuzumab biosimilars
-
1:53
dr. rugo discusses a comparative review of trastuzumab biosimilars
-
2:00
dr. rugo discusses advancements with biosimilars
-
7:22
an overview of biosimilarity
-
1:01:05
a-cell: generation of qtpp, risk assessment and critical quality attribute identification
-
3:33
biosimilars: manufacturing and inherent variation
-
10:17
dr. alay banker, improved his opd consultation by 1.5 times and saving 45 mins/day by using pd
-
5:58
the availability of multiple biosimilars for 1 biologic
-
1:48
dr. markman on the concept of biosimilars in oncology
-
4:53
optimal designs and analysis methods for the development of biosimilars
-
1:59
dr. lyman on the process for approving biosimilars
-
3:12
biosimilars: critical quality attributes
-
1:00
dr. dang on the significance of the myl-1401o biosimilar in her2-positive metastatic breast cancer
-
3:04
dr. rugo on 20-year span of breast cancer advancements
-
57:41
webinar: biologics & biosimilars
-
3:38
biosimilar trastuzumab
-
2:04
biosimilars: the path to approval
-
0:53
dr. schmid on evaluating biosimilars in oncology
-
0:59
dr. verma discusses biosimilars for trastuzumab
-
3:45
what are biosimilars? how do they work for arthritis?
-
5:56
the complexity of choosing biosimilars in oncology